Design, synthesis and evaluation of benzo[4,5]thiazolo[3,2-a]pyrimidin-4-one derivatives as novel MTA cooperative PRMT5 inhibitors for the treatment of MTAP-deleted cancers
Bioorganic Chemistry · 2026
DOI: 10.1016/j.bioorg.2026.110285 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026. Verfasst von Bing Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Anti-Infective Drug Discovery and Development, Sunshine Lake Pharma Co., Ltd., Dongguan 523871, PR China. Hauptthemen laut MEDLINE: Protein-Arginine N-Methyltransferases, Drug Design, Antineoplastic Agents, Enzyme Inhibitors. Die Arbeit nennt 22 Literaturangaben. Gefördert von: Dongguan Science and Technology Bureau, State Key Laboratory of Anti-Infective Drug Development.
Abstract (Originalsprache)
Protein arginine methyltransferase 5 (PRMT5) has emerged as a promising therapeutic target due to its critical roles in regulating fundamental cellular processes such as proliferation, migration, and differentiation. Although several PRMT5 inhibitors have been reported, but none have gained clinical approval. Herein, we describe the discovery of a novel series of benzo[4,5]thiazolo[3,2-a]pyrimidin-4-ones derivatives as MTA cooperative PRMT5 inhibitors. Compound 9u exhibited significant antiproliferative activity in MTAP-deleted HCT116 cancer cells, with an IC50 value of 13 nM, exhibiting 70-fold selectivity over MTAP wild type HCT116 cells. Furthermore, 9u displayed robust efficacy across diverse MTAP-deleted cancer cell lines, achieving IC50 values of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Anti-Infective Drug Discovery and Development, Sunshine Lake Pharma Co., Ltd., Dongguan 523871, PR China.
- Dongguan Key Laboratory of Fundamental Research and Clinical Application of Toxic Chinese Medicine, The First Dongguan Affiliated Hospital and School of Pharmacy, Guangdong Medical University, Dongguan 523121, PR China.
- State Key Laboratory of Anti-Infective Drug Discovery and Development, Sunshine Lake Pharma Co., Ltd., Dongguan 523871, PR China. Electronic address: ZhangYingjun@hec.cn.
- Dongguan Key Laboratory of Fundamental Research and Clinical Application of Toxic Chinese Medicine, The First Dongguan Affiliated Hospital and School of Pharmacy, Guangdong Medical University, Dongguan 523121, PR China;…
Förderung
- Dongguan Science and Technology Bureau
- State Key Laboratory of Anti-Infective Drug Development
Zitieren
APA
Liu, B., Li, S. Y., Shi, H., Hu, X. J., Pan, X. G., Liu, J. S., Zhuang, Z., Kang, N., Wang, Q., Zhang, Y. J., & Yang, F. (2026). Design, synthesis and evaluation of benzo[4,5]thiazolo[3,2-a]pyrimidin-4-one derivatives as novel MTA cooperative PRMT5 inhibitors for the treatment of MTAP-deleted cancers. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2026.110285
Vancouver
Liu B, Li SY, Shi H, Hu XJ, Pan XG, Liu JS, et al. Design, synthesis and evaluation of benzo[4,5]thiazolo[3,2-a]pyrimidin-4-one derivatives as novel MTA cooperative PRMT5 inhibitors for the treatment of MTAP-deleted cancers. Bioorganic Chemistry. 2026. doi:10.1016/j.bioorg.2026.110285
BibTeX
@article{Liu2026,
author = {Liu, Bing and Li, Shao-Yan and Shi, Hui and Hu, Xian-Jing and Pan, Xiao-Guang and Liu, Jin-Shan and Zhuang, Ze and Kang, Ning and Wang, Qian and Zhang, Ying-Jun and Yang, Fang},
title = {Design, synthesis and evaluation of benzo[4,5]thiazolo[3,2-a]pyrimidin-4-one derivatives as novel MTA cooperative PRMT5 inhibitors for the treatment of MTAP-deleted cancers},
journal = {Bioorganic Chemistry},
year = {2026},
doi = {10.1016/j.bioorg.2026.110285}
}
EUVIMED